Impact of long-term antiretroviral therapy on gut and oral microbiotas in HIV-1-infected patients

Sci Rep. 2021 Jan 13;11(1):960. doi: 10.1038/s41598-020-80247-8.

Abstract

In HIV-1-infected patients, antiretroviral therapy (ART) is a key factor that may impact commensal microbiota and cause the emergence of side effects. However, it is not fully understood how long-term ART regimens have diverse impacts on the microbial compositions over time. Here, we performed 16S ribosomal RNA gene sequencing of the fecal and salivary microbiomes in patients under different long-term ART. We found that ART, especially conventional nucleotide/nucleoside reverse transcriptase inhibitor (NRTI)-based ART, has remarkable impacts on fecal microbial diversity: decreased α-diversity and increased ß-diversity over time. In contrast, dynamic diversity changes in the salivary microbiome were not observed. Comparative analysis of bacterial genus compositions showed a propensity for Prevotella-enriched and Bacteroides-poor gut microbiotas in patients with ART over time. In addition, we observed a gradual reduction in Bacteroides but drastic increases in Succinivibrio and/or Megasphaera under conventional ART. These results suggest that ART, especially NRTI-based ART, has more suppressive impacts on microbiota composition and diversity in the gut than in the mouth, which potentially causes intestinal dysbiosis in patients. Therefore, NRTI-sparing ART, especially integrase strand transfer inhibitor (INSTI)- and/or non-nucleotide reverse transcriptase inhibitor (NNRTI)-containing regimens, might alleviate the burden of intestinal dysbiosis in HIV-1-infected patients under long-term ART.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Anti-HIV Agents / therapeutic use*
  • Dysbiosis / drug therapy
  • Dysbiosis / microbiology
  • Dysbiosis / virology
  • Female
  • Gastrointestinal Microbiome / drug effects*
  • HIV Infections / drug therapy*
  • HIV Infections / microbiology*
  • HIV Infections / virology
  • HIV Seropositivity / drug therapy
  • HIV Seropositivity / virology
  • HIV-1 / drug effects
  • Humans
  • Male
  • Middle Aged
  • Mouth / microbiology*
  • Reverse Transcriptase Inhibitors / therapeutic use

Substances

  • Anti-HIV Agents
  • Reverse Transcriptase Inhibitors